About Kesmalea
Kesmalea is a company based in London (United Kingdom) founded in 2020 by Harry Finch. Kesmalea has raised $62.03 million across 4 funding rounds. Kesmalea offers products and services including SELFTAC Platform and Therapeutics Pipeline. Kesmalea operates in a competitive market with competitors including Nuclera Nucleics, Encodia, Tierra Biosciences, Amide Technologies and mk2 Biotechnologies, among others.
- Headquarter London, United Kingdom
- Founders Harry Finch
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$62.03 M (USD)
in 4 rounds
-
Latest Funding Round
$13.14 M (USD), Series B
Sep 03, 2024
-
Investors
Not available
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Kesmalea
Kesmalea offers a comprehensive portfolio of products and services, including SELFTAC Platform and Therapeutics Pipeline.
Converts large protein degraders into small molecules for disease treatment
Advances novel drugs for oncology and CNS via targeted degradation
People of Kesmalea
Unlock access to complete
Funding Insights of Kesmalea
Kesmalea has successfully raised a total of $62.03M across 4 strategic funding rounds. The most recent funding activity was a Series B round of $13.14 million completed in September 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investments & Acquisitions by Kesmalea
Investment portfolio details for Kesmalea
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Kesmalea
Detailed financials for Kesmalea
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Kesmalea Comparisons
Peer comparison for Kesmalea
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Kesmalea
Kesmalea operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Nuclera Nucleics, Encodia, Tierra Biosciences, Amide Technologies and mk2 Biotechnologies, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Desktop bioprinter for genes and proteins production is developed.
|
|
| Locked | Locked | Locked |
Technology platforms for integrative proteomic analysis are developed.
|
|
| Locked | Locked | Locked |
AI-based tools for protein development and custom synthesis are offered.
|
|
| Locked | Locked | Locked |
Automated peptide synthesis platform is developed with precision reagents.
|
|
| Locked | Locked | Locked |
Peptides and proteins are developed for life science applications.
|
Detailed competitors of Kesmalea
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Kesmalea
Complete news archive for Kesmalea
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Kesmalea
Kesmalea was founded in 2020 and raised its 1st funding round 2 years after it was founded.
Kesmalea is headquartered in London, United Kingdom. It is registered at London, England, United Kingdom.
Kesmalea is a funded company, having raised a total of $62.03M across 4 funding rounds to date.
Kesmalea was founded in 2020 and is based in London, United Kingdom. Operations are centered in the biotechnology sector, where novel protein degraders are discovered to maintain protein equilibrium in the human body. An intricate system is employed for the continuous synthesis and regulation of proteins, targeting therapeutic applications in healthcare.
Kesmalea's top competitors include Nuclera Nucleics, Encodia and Tierra Biosciences.
Kesmalea offers SELFTAC Platform and Therapeutics Pipeline.